x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012175
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human iNOS protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NOS2 |
| UniProt No. | P35228 |
| Gene ID | 4843 |
| Gene Description | Nitric Oxide Synthase catalyzes the formation of nitric oxide and citrulline from L-arginine, oxygen, and cofactors. Three family members have been characterized: neuronal NOS, which is found primarily in neuronal tissue; inducible NOS, which is induced by interferon gamma and lipopolysaccharides in the kidney and cardiovascular system; and endothelial NOS, which is expressed in blood vessels. NO is a messenger molecule with diverse functions throughout the body, including the maintenance of vascular integrity, homeostasis, synaptic plasticity, long-term potentiation, learning, and memory.NO catalyzed by iNOS is involved in host defense against protozoa, bacteria, fungi, and viruses., like constitutively expressed eNOS and nNos, iNOS is not usually expressed in quiescent cells. iNOS is transcriptionally induced in response to bacterial endotoxins, such as LPS and proinflammatory cytokines, in macrophages and various other cell types. Transcription factors involved in iNOS transcription include NF-κB, AP-1, and STAT. Different signaling pathways either promote or inhibit iNOS expression depending on stimulus and cell type. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
